deltatrials
Active Not Recruiting PHASE3 INTERVENTIONAL 2-arm NCT02413736

Three Versus Five Years of Adjuvant Imatinib as Treatment of Patients With Operable GIST

Three Versus Five Years of Adjuvant Imatinib as Treatment of Patients With Operable GIST With a High Risk for Recurrence: A Randomised Phase III Study

Sponsor: Heikki Joensuu

Conditions Sarcoma
Interventions Imatinib
Updated 14 times since 2017 Last updated: Mar 10, 2025 Started: May 31, 2015 Primary completion: Jun 30, 2026 Completion: Jun 30, 2033
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT02413736, this PHASE3 trial focuses on Sarcoma and remains ongoing. Sponsored by Heikki Joensuu, it has been updated 14 times since 2015, reflecting substantial change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

~Jan 2017 – ~Jun 2018 · 17 months · monthly snapshot~Jun 2018 – ~Sep 2018 · 3 months · monthly snapshot~Sep 2018 – ~Mar 2020 · 18 months · monthly snapshot~Mar 2020 – ~Dec 2020 · 9 months · monthly snapshot~Dec 2020 – ~Jan 2021 · 31 days · monthly snapshot~Jan 2021 – ~Jan 2022 · 12 months · monthly snapshot~Jan 2022 – ~Sep 2022 · 8 months · monthly snapshot~Sep 2022 – ~Jul 2023 · 10 months · monthly snapshot~Jul 2023 – ~Aug 2023 · 31 days · monthly snapshot~Aug 2023 – ~Dec 2023 · 4 months · monthly snapshot~Dec 2023 – ~Jul 2024 · 7 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Apr 2025 · 7 months · monthly snapshot~Apr 2025 – present · 15 months · monthly snapshot

Change History

14 versions recorded

  1. Apr 2025 — Present [monthly]

    Active Not Recruiting PHASE3

  2. Sep 2024 — Apr 2025 [monthly]

    Active Not Recruiting PHASE3

  3. Jul 2024 — Sep 2024 [monthly]

    Active Not Recruiting PHASE3

  4. Dec 2023 — Jul 2024 [monthly]

    Active Not Recruiting PHASE3

  5. Aug 2023 — Dec 2023 [monthly]

    Active Not Recruiting PHASE3

▶ Show 9 earlier versions

  1. Jul 2023 — Aug 2023 [monthly]

    Active Not Recruiting PHASE3

    Status: Recruiting → Active Not Recruiting

  2. Sep 2022 — Jul 2023 [monthly]

    Recruiting PHASE3

  3. Jan 2022 — Sep 2022 [monthly]

    Recruiting PHASE3

  4. Jan 2021 — Jan 2022 [monthly]

    Recruiting PHASE3

  5. Dec 2020 — Jan 2021 [monthly]

    Recruiting PHASE3

  6. Mar 2020 — Dec 2020 [monthly]

    Recruiting PHASE3

  7. Sep 2018 — Mar 2020 [monthly]

    Recruiting PHASE3

  8. Jun 2018 — Sep 2018 [monthly]

    Recruiting PHASE3

  9. Jan 2017 — Jun 2018 [monthly]

    Recruiting PHASE3

    First recorded

May 2015

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Heikki Joensuu
  • Scandinavian Sarcoma Group
Data source: Helsinki University Central Hospital

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations